Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approved

[cafead]

via Bluebird bio (BLUE.O) said on Monday it has agreed to sell its priority review voucher for $103 million if it gets the U.S. Food and Drug Administration's approval for its gene therapy to treat sickle cell disease.

article source